International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPhase 1 Study of Dose Escalation in Hypofractionated Proton Beam Therapy for Non-Small Cell Lung Cancer
Introduction
Non-small cell lung cancer (NSCLC) is frequently diagnosed in patients of an advanced age who are likely to have additional comorbid conditions and poor performance status, making them unable to tolerate standard chemoradiation therapy 1, 2, 3. Effective regimens that omit concurrent systemic therapy are needed for such patients. In addition, if shorter radiation courses could be delivered for locally advanced disease, patients who could tolerate it could receive systemic doses of sequential chemotherapy sooner than would otherwise be possible, which could reduce the risk of distant metastases and increase the cost effectiveness of radiation by reducing the number of fractions to be given.
Numerous studies have been published regarding hypofractionated stereotactic radiation therapy for early-stage lung cancer (4), but analyses of hypofractionated regimens for locally advanced disease are limited. One institution reported 2 studies in which 45 Gy in 3-Gy fractions was given to patients with poor performance status and noted that rates of response and locoregional control were comparable despite poor prognostic factors 5, 6. The advent of increasingly conformal techniques may allow further dose escalation to improve the likelihood of local control while sparing surrounding normal structures.
To address this possibility, we undertook this prospective phase I study to assess the safety of dose-escalating hypofractionated proton therapy, given without chemotherapy, for NSCLC. Our hypothesis was that the favorable dose-distribution characteristics of proton beam therapy (PBT) would render doses of up to 60 Gy(RBE) (biologically equivalent dose [BED] 84 Gy) feasible even for patients with poor performance status.
Section snippets
Patients
This study was approved by the appropriate institutional review board. Eligibility criteria included histologically or cytologically documented NSCLC. Multiple histologies were initially allowed because of the phase 1 nature of the study, but to maintain uniformity, only the results with NSCLC are included in this report. Concurrent chemotherapy was not allowed, but concurrent treatment with biologic agents such as epidermal growth factor receptor (EGFR) or vascular endothelial growth factor
Results
Twenty-five patients with NSCLC were enrolled in this trial. Patient characteristics are shown in Table 2. Sixty-four percent of patients had mediastinal involvement, including those who did not have NSCLC. Patients without mediastinal involvement were included in this study if their tumors were thought to be too large (typically >4 cm) or too centralized (ie, adjacent to the mediastinum or bronchial tree) to be treated with stereotactic ablative body radiation. No DLT was experienced during
Discussion
Pertinent findings from this phase 1 dose-escalation study of an intermediate hypofractionated regimen for NSCLC were as follows. First, the modified dose constraints used were effective, both in allowing treatment of patients with extensive mediastinal disease and in limiting the rate of high-grade acute toxicity. Second, hypofractionated regimens up to 60 Gy(RBE) in 15 fractions were tolerated well in most cases, even when patients were not candidates for systemic therapy because of poor
Acknowledgment
The authors thank Christine Wogan, MS, ELS, for reviewing and editing the manuscript of this article.
References (20)
- et al.
Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review
Int J Radiat Oncol Biol Phys
(1999) - et al.
Four-dimensional proton treatment planning for lung tumors
Int J Radiat Oncol Biol Phys
(2006) - et al.
4D Proton treatment planning strategy for mobile lung tumors
Int J Radiat Oncol Biol Phys
(2007) - et al.
Methodologies and tools for proton beam design for lung tumors
Int J Radiat Oncol Biol Phys
(2001) - et al.
Dose-finding in phase I clinical trials based on toxicity probability intervals
Clin Trials
(2007) - et al.
A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer
Radiother Oncol
(2011) - et al.
Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer
Int J Radiat Oncol Biol Phys
(2013) - et al.
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy
Int J Radiat Oncol Biol Phys
(2010) - et al.
Tracheo-esophageal fistula with bevacizumab after mediastinal radiation
J Thorac Oncol
(2008) - et al.
Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy
J Thorac Oncol
(2009)
Cited by (0)
Supported in part by NCI Cancer Center Support (core) Grant CA16672 and P01 CA021239.
Conflict of interest: none.